We've reshaped the future of genomics
We are on a mission to transform human health and the world we live in by developing innovative technologies that unleash the potential of genomics.
Diagnosis to treatment in days not weeks!
We are thrilled to announce the launch of ASPYRE-Lung, reducing the time to obtain vital biomarker data from weeks to days. ASPYRE-Lung identifies all guideline recommended biomarkers that correlate with more than 25 life-saving targeted therapies for patients with lung cancer, in a fraction of the time and at a fraction of the cost of sequencing technologies.
At Biofidelity, we believe every patient deserves the best treatment options. We are committed to overcoming barriers that have prevented hundreds of thousands of patients from experiencing the exceptional benefits of targeted therapies.
Simple answers to complex questions
Genomics impacts humanity in ways that were previously unimaginable. Yet genomic analysis remains complex and costly, limiting its full potential and making it inaccessible to many people around the world. Biofidelity’s novel technology removes the noise from genomic data, providing only the information needed to make decision-making less complex, faster and more accurate. Our mission is to transform human health and the world we live in, and we won’t stop until there is genomics for all.
Technology & products
ASPYRE® is a patented molecular chemistry that uses a unique enzymatic reaction to dramatically simplify and accelerate the detection of actionable genomic biomarkers. With ASPYRE, precision genomic testing can be carried out using existing PCR instruments, of which there are more than 100,000 globally, bringing the benefits of precision medicine to far more patients around the world.
ASPYRE®-Lung is a comprehensive lung panel that simultaneously analyzes DNA and RNA from blood or tissue in a single assay, enabling straightforward, precise identification of all NCCN guideline recommended genomic biomarkers associated with approved targeted therapies for non-small cell lung cancer patients.
ENSPYRE is a revolutionary genomic enrichment technology designed to remove more than 99% of uninformative DNA prior to sequencing. By eliminating background DNA, ENSPYRE massively reduces the amount of data needed to answer genomic questions, while increasing accuracy from a fraction of the sequencing depth. Fitting seamlessly into existing NGS workflows, ENSPYRE can be applied across a wide range of applications, from research and discovery to clinical diagnosis.
Featured news & resources
Biofidelity announces the commercial launch of ASPYRE®-Lung in the US
CAMBRIDGE, UK and RESEARCH TRIANGLE PARK, NORTH CAROLINA, USA, September 5,...
Biofidelity Introduces ASPYRE®-Lung at ASCO 2023
ASPYRE simplifies and accelerates the detection of actionable biomarkers in...
Matt Franklin, MBA, appointed as Biofidelity Non-Executive Director
CAMBRIDGE, UK and RESEARCH TRIANGLE PARK, NORTH CAROLINA, USA, November 17,...